Navigation Links
GenturaDx Appoints Senior Vice President of Research & Development
Date:7/11/2011

HAYWARD, Calif., July 11, 2011 /PRNewswire/ -- Molecular diagnostics company GenturaDx announced today that Geoffrey A. McKinley, Ph.D., has joined the company as Senior Vice President of Research & Development.  McKinley joins as GenturaDx accelerates research to bring its IDbox™ System to commercialization.

(Photo:  http://photos.prnewswire.com/prnh/20110711/LA32940)

"With his depth of experience developing molecular diagnostic products, Geoff will be a key asset in commercializing our molecular platform in the next 12 to 24 months," said Mark Bagnall, GenturaDx's chief executive officer. "GenturaDx anticipates completing beta studies this year and clinical studies in 2012, and Geoff is an important addition to a talented R & D team working to perfect our system as well as develop partnerships with companies that seek to adapt assay content to our platform."

Dr. McKinley brings to GenturaDx nearly two decades of research & development and business development experience related to developing molecular diagnostic products and tools for infectious diseases.  Prior to joining GenturaDx, Dr. McKinley was responsible for research & development to support molecular biology assay, consumable and instrumentation development at Osmetech, Inc. He has previously held positions at Naxcor, Inc., BioMerieux, Inc., and Analytab Products, a division of Sherwood Medical. Dr. McKinley earned his Ph.D. at Colorado State University.

"It's a great time to be at GenturaDx," Dr. McKinley said, "because its unique, PCR-based, sample-to-answer IDbox System has the potential to dramatically impact molecular diagnostics, offering potential performance advantages over existing systems on the market and making the molecular testing affordable and easy to use for the estimated 5,000 small-to-medium sized hospitals that rely on traditional culture techniques or immunoassay testing."

About GenturaDx

GenturaDx is a molecular diagnostic company focused on making molecular diagnostics both affordable and practical for any laboratory to perform.  The company's IDbox System incorporates all aspects of proprietary, real-time PCR testing from sample preparation through result generation in a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide – circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform reduces the risk of contamination and saves time; the platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test.


'/>"/>
SOURCE GenturaDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Appoints New Chief Medical Officer
2. West Pharmaceutical Services, Inc. Appoints New Director
3. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
4. Curemark Appoints Preeminent Pediatrics Gastroenterologist
5. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. Cytopia Appoints Study Chairman for JAK2 Clinical Trial
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. NovaRx Appoints Industry Veteran as President and COO
10. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
11. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):